co-presented by
ASSOCIATE SPONSORS
co-presented by
ASSOCIATE SPONSORS
Consumers and patients are advised to be careful and only procure the medical products from authorised sources with proper purchase invoice
Adynovate is an innovative extended half-life recombinant Factor VIII (rFVIII) treatment, using established technology for hemophilia A patients. It offers effective bleed resolution with closer-to-zero spontaneous bleed in majority, better joint health and reduces infusion frequency and associated pain, the company said in a statement.
The phase 3 trial by the group, known as the CoVIg Plasma Alliance, aims to enroll 500 adult patients from the United States, Mexico and 16 other countries, according to a statement.
Major pharma companies in Japan have scaled down their sales forces to cope with a shrinking market and cuts in drug prices imposed by the national health system.
Under lysosomal storage disorders, India has been recording the prevalence of Hunter syndrome, Gaucher disease and Fabry disease.
After the Shire deal, which closes on January 8, Takeda will have a stronger pipeline and be counted among the top 10 drugmakers by sales globally.
The agreement includes early stage development to the final commercialisation of the vaccine.
Sun Pharmaceutical Industries Ltd said its unit has received US Food and Drug Administration's final approval for the generic version of Prevacid.
Shares in Sun Pharmaceutical Industries, India's most valued drugmaker, rose as much as 2.5 percent after its unit agreed to buy the generic drugs business of US-based URL Pharma from Japan's Takeda Pharmaceutical Co.
Advinus Therapeutics Ltd (Advinus)and Japanese firm Takeda Pharmaceutical Company Ltd (Takeda) jointly announced today that they have entered into an agreement to initiate a three-year drug discovery collaboration.
Pharmaceutical companies Cipla and Lupin have both strongly denied that they are in talks with Takeda Pharmaceutical Co to sell stake or part of their business, and have said a newspaper report linking the two with the Japanese firm is "baseless."
Takeda Pharmaceutical Co, Japan's largest drugmaker, is in talks with Indian generic drugmakers Cipla and Lupin about buying one of the companies' pharmaceutical businesses.
